Acute promyelocytic leukemia (APL) is characterized by the translocation t(15;17)(q22;q21), resulting in the promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) fusion protein 1 in 95% cases whereas variant translocations involving PLZF (11q23), NPM (5q35), NUMA (11q13) and STAT5b (17q23) account for the rest. 2 Leukemias with PML-RARA translocations respond well to all-trans retinoic acid (ATRA) or arsenic trioxide (ATO) therapy 3 whereas those with PLZF-RARA fusions respond poorly. Although primary resistance to ATRA is rare, secondary or acquired resistance is frequently observed in patients treated with ATRA alone or in combination with other chemotherapy regimens. However, molecular abnormalities mediating resistance to ATRA therapy are underexplored. Here, we report two cases of APL with RARA-PML deletions on der(17) or der(15), which displayed clinical evidence of primary and secondary resistance to therapy, respectively. (Figure 1a) . Fluorescence in situ hybridization (FISH) analysis using PML/RARA dual fusion probes detected an unusual signal pattern in 74.6% cells (one fused, one green, one red signal) instead of the expected pattern (two fused; one on each derivative chromosome, one red, and one green on normal 15 and 17, respectively). Analysis of metaphases allowed mapping of the deleted fusion signal to der(17)t(15;17) ( Figure 1d ) and showed a residual PML signal on der(17) (Figure 1d ), suggesting that the deletion encompassed a major part of the 3 0 end of PML and the entire 5 0 end of RARA on der(17)t(15;17). On further examination of metaphase preparations, one (16%) or Letters to the Editor two (36%) copies of ider(17)(q10)t(15;17) were also identified (Figure 1b-c and e). Spectral karyotype (SKY) analysis, performed to rule out other cryptic abnormalities, confirmed the t(15;17)(q22;q21) and ider(17)(q10)t(15;17) (Figure 1b and c) .
The patient achieved hematologic remission after treatment with ATRA and idarubicin. However, a bone marrow biopsy 30 days post-therapy showed dysplastic myeloid maturation and flow cytometry detected 2% blasts. Karyotype analysis showed 46,XY,t(15;17)(q22;q21) [6] /46,XY [14] and FISH with PML/ RARA probes confirmed t(15;17) in 69.7% cells with a single fusion signal. These findings were consistent with primary resistance to therapy. After re-induction therapy with addition of ATO, the patient is currently in complete hematologic and cytogenetic remission.
Patient 2 is 18-year-old female presented with 2 days of petechiae and intra-cranial hemorrhage. The initial white blood cell count was 38 000 Â 10 6 /l and platelet count was 15 000 Â 10 6 /l. Review of the marrow aspirate showed 90% blasts, many with Auer rods, which had morphologic features of 'typical' APL. Flow cytometry detected 80% blasts with the phenotype: [3] . FISH analysis using PML/RARA probes revealed 96.3% cells with rearrangement and deletion of PML on der(15) (Figure 2b-d) , which was suggestive of a deletion involving the 5 0 end of PML gene on der(15). To determine the size of this deletion, we performed FISH utilizing probes flanking both sides of the PML breakpoint. FISH analysis with a 96 kb bacterial artificial chromosome (BAC) clone spanning intron 4 and all of the 3 0 end of the PML breakpoint confirmed retention of the 3 0 end of the translocated PML on der(17) and a residual signal on der(15), consistent with the PML breakpoint being distal to exon 5 ( Figure 2f ). Two BAC clones spanning À376 to À107 kb 5 0 of the PML gene, showed no evidence of deletions on der(15) (Figure 2e ). The size of the deletion was estimated to be 100-150 kb based on loss of the major portion of the 5 0 end of PML and retention of signals upstream of the PML gene. These data suggest that PML deletion on der(15) might be responsible with secondary resistance to therapy. After re-induction with Letters to the Editor ATO þ ATRA, the patient is in complete remission 1 month postmismatched unrelated donor stem cell transplant.
Submicroscopic deletions associated with chromosomal translocations/inversions have been documented in chronic myeloid leukemia (CML) and leukemias with t(8;21), inv(16)/ t(16;16), or mixed lineage leukemia translocations. 4 Deletions in CML patients have been associated with refractory disease and a poor outcome. 5 Chromosomal deletions associated with t(15;17) have not been reported in APL. 4 Similar to CML, submicroscopic deletions in our first case encompassed a large region (B300 kb) 3 0 of the PML gene and the entire 5 0 of the RARA gene including exons 1 and 2, spanning a region of B250 kb. The Her-2/neu gene, which maps 580 kb proximal to RARA, was retained (Figure 1e, f) suggesting that the deletion breakpoint on der(17) was between 250 and 500 kb centromeric to RARA. To our knowledge, this is the first described case of APL that demonstrated chromosomal deletions in association with a RARA/PML translocation and exhibited primary resistance to ATRA-based therapy. We propose that the genetic deletions on either side of the translocation on 17q might be responsible for the primary resistance. The 300 kb deleted region, distal to PML on der(17q), contains ISLR, STRA6 and CYP11A1 and loss of one of these genes might account for resistance to therapy. The 400 kb genomic region proximal to 5 0 RARA on 17q is a gene-rich region, which contains CDC6, WIRE, RAPGEFL1, CASC3, NR1D1, THRA, THRAP4, CSF3, PSMD3, GSDM1, ORMDL3, GSDML and SPBP2. Haploinsufficiency of some of these genes may function as tumor suppressors or modifiers. The ider(17) chromosome resulted in TP53 gene deletion (data not shown), which may further contribute to growth advantage and treatment resistance. Thus, as in CML, large deletions accompanying translocations in APL might impart a proliferative advantage, resistance to cell death, or lead to differentiation arrest.
Primary resistance of APL with t(15;17) to ATRA induction therapy is rare but secondary resistance and relapse of disease after clinical remission has been described. Deletions in the carboxy terminus of PML exon 6, 6 mutations of the normal PML allele 7 and insertions in RARA intron 2 8 have been shown to reduce sensitivity to maturation inducing agents and secondary resistance to therapy. Our second case demonstrated a B100 kb deletion in the amino terminus of PML, 5 0 of exon 6 on der(15). Two genes, STOML1 (À12 kb) and LOXL1 (À68 kb), that map immediately upstream are the likely targets of this deletion. Although the function of STOML1 is unknown, LOXL1 is implicated in developmental regulation, senescence, tumor suppression, cell growth control and chemotaxis. Haploinsufficiency or loss of function of these genes may play a role in secondary resistance. Further studies are needed to delineate the frequency of submicroscopic deletions in APL and their molecular and clinical consequence. 
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